Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243007 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02243007: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02243007 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243007, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
Primary Outcome
Number of participants surviving after 18 months of study follow-up
Interventions
- DRUG Capecitabine
- RADIATION Radiation therapy
- DRUG FOLFIRINOX
- DRUG Gemcitabine/nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Why NCT02243007 stopped before completion
NCT02243007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT02243007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02243007 about?
NCT02243007 is a clinical study titled "Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer". This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
What is the current status of trial NCT02243007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02243007?
The interventions under investigation include: Capecitabine (DRUG), Radiation therapy (RADIATION), FOLFIRINOX (DRUG), Gemcitabine/nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02243007?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02243007's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia